BioStock: Further steps in Aptahem's phase I study

At the end of December 2022, biotech company Aptahem announced the completion of cohort 1 in healthy volunteers for the phase I study with the sepsis candidate Apta-1. Now, the second dose cohort is also ready and approved by the Dutch Ethics Committee and dose cohort three has started. BioStock talked to CEO Mikael Lindstam to learn more.

Read the full interview with Aptahem´s CEO Mikael Lindstam at biostock.se:

https://www.biostock.se/en/2023/02/further-steps-in-aptahems-phase-i-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/